Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia.
about
Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies.Diagnosis and management of heparin-induced thrombocytopenia.Bivalirudin: a review.Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia: treatment options and special considerations.Heparin-induced thrombocytopenia and recent advances in its therapy.Current concepts review: heparin-induced thrombocytopenia.Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.Fondaparinux: does it cause HIT? Can it treat HIT?An overview of heparin-induced thrombocytopenia.Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.Heparin-induced thrombocytopenia in the pediatric population: a review of current literaturePulmonary embolism caused by delayed heparin-induced thrombocytopenia in a patient who received prophylactic LMWH.Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring systemLow-molecular-weight heparin for the treatment of venous thromboembolism in the elderly.Superficial vein thrombosis.Anticoagulation in pregnancy: a survey of current practice.Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal.Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux.Widespread skin necrosis associated with unfractionated heparin therapy in a patient under chronic coumarin anticoagulation.The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products.
P2860
Q33365296-CE9B59E1-DA1C-403D-ACD9-7D3041AF6990Q33365985-F9A55E95-7C6C-4143-ABBC-A3D56A6ADB66Q33367230-EC82DA40-6C27-4219-BB08-0076619927CAQ33374563-3F131A00-BDE2-4317-8AC2-A3680DCACB9FQ33374658-2BF122F6-84EB-4166-8656-772F98BB8586Q33377436-1DD55E71-80DE-4063-9784-054D04216A2CQ33382108-B3CC7AF9-5795-4758-9B82-3D8CE437B29AQ33387713-C36CCF76-50F0-4F1C-81C0-9AB5BFC13731Q33392864-82522AB6-14F9-4B93-A564-77E96CAE9B8BQ33394986-13B31202-1F77-4B1B-9B55-C89CF387F139Q33396967-20769C93-36CC-4A0E-AC21-DC18DDB387B8Q33401236-C1F0968C-F2CC-4E74-8203-9F4D891CCCF3Q33402572-829A0184-6609-444B-A0AD-754C8AB3DD7DQ33404178-7FE083DA-79F2-45B1-A2A9-E2D06E2BF5AEQ33406965-1C7CCB10-1520-470D-9002-280A0DD4AC45Q33418994-80047C4E-1CEF-4DC2-ADCC-005217B1D834Q36022983-96ABF726-30C1-47B9-B10D-6DC71B4070ADQ43905870-FA80318C-38D8-4BF8-B46C-9C8D568E220DQ44693251-963AC20F-CF7F-4812-AD7C-04B8743A33C6Q46069546-4F8EC6B1-8BFC-4789-B1CD-35F0FBBD5695Q46855028-30F90442-C032-4775-B4CD-3387F6F54270Q46965139-9B435BD9-C181-4C8E-9C41-5E1B2B7C8705Q47253148-0764088D-9BDC-4B84-B8F0-73A98BFBEEE9
P2860
Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Biological and clinical featur ...... arin-induced thrombocytopenia.
@ast
Biological and clinical featur ...... arin-induced thrombocytopenia.
@en
type
label
Biological and clinical featur ...... arin-induced thrombocytopenia.
@ast
Biological and clinical featur ...... arin-induced thrombocytopenia.
@en
prefLabel
Biological and clinical featur ...... arin-induced thrombocytopenia.
@ast
Biological and clinical featur ...... arin-induced thrombocytopenia.
@en
P2093
P2860
P1476
Biological and clinical featur ...... arin-induced thrombocytopenia.
@en
P2093
Annie Derlon
Claire Pouplard
French Heparin-Induced Thrombocytopenia Study Group
Irène Juhan-Vague
Jeanne-Yvonne Borg
Michel Samama
Philippe Nguyen
Véronique Regnault
Yves Gruel
P2860
P304
P356
10.1046/J.1365-2141.2003.04363.X
P407
P577
2003-06-01T00:00:00Z